VICP Stock Overview
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Vicapsys Life Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.99 |
52 Week High | US$3.00 |
52 Week Low | US$1.03 |
Beta | -5.95 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | -17.43% |
Change since IPO | -43.14% |
Recent News & Updates
Recent updates
Shareholder Returns
VICP | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -1.6% | -0.3% |
1Y | n/a | 10.2% | 28.4% |
Return vs Industry: Insufficient data to determine how VICP performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how VICP performed against the US Market.
Price Volatility
VICP volatility | |
---|---|
VICP Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 17.0% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VICP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VICP's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 2 | Fred Pier | https://vicapsys.com |
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
Vicapsys Life Sciences, Inc. Fundamentals Summary
VICP fundamental statistics | |
---|---|
Market cap | US$63.82m |
Earnings (TTM) | -US$1.08m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-59.1x
P/E RatioIs VICP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VICP income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$1.08m |
Earnings | -US$1.08m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.034 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -23.0% |
How did VICP perform over the long term?
See historical performance and comparison